华东医药索米妥昔单抗注射液补充申请获批

Core Viewpoint - The approval of the supplemental application for the drug Somatuzumab injection (brand name: ELAHERE) marks a significant milestone in the product's development process for the company [1] Company Summary - The company's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the supplemental application of Somatuzumab injection [1] - The company plans to actively promote the commercialization of ELAHERE in the Chinese market, aiming to provide better clinical treatment options for relevant patients [1]